Q-omics provides the consensus-scored CERNA3 profile across patient tissues and cancer cell-line models. CERNA3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CERNA3 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, CERNA3 RNA expression shows 7,662 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, KICH, and LSCC as cancer lineages where CERNA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CERNA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CERNA3 survival associations across molecular data types. CERNA3 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CERNA3 RNA expression–survival associations across cancer types. High CERNA3 expression shows unfavorable associations in THYM, UVM, KICH, LIHC and MESO, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for CERNA3 RNA expression.
This table summarizes CERNA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CERNA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CERNA3 shows lower tumor expression in KICH and higher tumor expression in LUAD, LIHC, HNSC, BRCA and LUSC. The KICH box plot shows higher CERNA3 RNA expression in normal versus tumor tissue (log2 FC = −0.182, t-test p = .002).
This table shows molecular features associated with CERNA3 in patient tissues and cancer cell lines. In patient samples, CERNA3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
